Advances in Alzheimer's disease's pharmacological treatment

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Alzheimer's disease (AD) is the leading cause of dementia in older adults.
• Despite extensive research, effective neuroprotective or regenerative treatments for AD are lacking.
• Ongoing efforts focus on identifying novel molecular targets for AD drug development.

Purpose of the Study:

• To review and summarize recent advancements in pharmacological therapies for Alzheimer's disease.
• To analyze clinical trial data based on molecular targets, therapeutic outcomes, and safety profiles.

Main Methods:

• Systematic analysis of clinical trials registered in the National Library of Medicine database.
• Categorization of trials by molecular targets, observed therapeutic effects, and safety assessments.

Main Results:

• The predominant outcome across analyzed trials was a lack of efficacy.
• Seven trials reported drugs that were both safe and demonstrated some therapeutic improvement.
• Three studies indicated therapeutic benefits accompanied by toxicity.
• Antibodies targeting amyloid-beta (Aβ), despite recent approvals, yielded limited significant results.
• Approaches targeting 5-HT6 receptors, tau, and nicotinic agonists showed discouraging outcomes.

Conclusions:

• Current Alzheimer's disease drug development faces significant challenges, with many trials reporting inefficacy.
• Emerging therapeutic strategies, including anti-amyloid-beta vaccines, BACE inhibitors, and anti-neuroinflammation agents, show promise.
• Further research and development are crucial for effective Alzheimer's disease treatment.